

## **Radiation Therapy Extra-Cranial Metastases Request**

For NON-URGENT requests, please complete this document for authorization along with any relevant clinical documentation requested within this document (i.e. radiation therapy consultation, comparison plan, etc.) before submitting the case by web, phone, or fax. Failure to provide all relevant information may delay the determination. Phone and fax numbers can be found on eviCore.com under the Guidelines and Fax Forms section. You may also log into the provider portal located on the site to submit an authorization request. URGENT (same day) requests must be submitted by phone.

| Patient/<br>Member   | First Name:  |        |        | Middle Initial: |                |                     | Last Name: |  |  |  |  |
|----------------------|--|--------|--------|-----------------|----------------|---------------------|------------|--|--|--|--|
|                      | DOB (mm/dd/yyyy):  |        |        |                 |                | Gender: Male Female |            |  |  |  |  |
|                      | Health Pla   |        |        | N               | Member ID:     |                     |            |  |  |  |  |
|                      | · · · · · · · · · · · · · · · · · · ·  |        |        |                 |                |                     |            |  |  |  |  |
| Clinical Information | ICD-10 Code(s):  |        |        |                 |                |                     |            |  |  |  |  |
|                      | What is the radiation therapy treatment start date (mm/dd/yyyy)?   |        |        |                 |                |                     |            |  |  |  |  |
|                      | eviCore is utilizing a clinical decision support submission model for this diagnosis.  Please note that only some of the following example questions will need to be answered during the submission of your prior authorization request. |        |        |                 |                |                     |            |  |  |  |  |
|                      | For best results, the answers to these questions should be submitted online.   |        |        |                 |                |                     |            |  |  |  |  |
|                      | What is the location of the metastatic site(s) that will be treated? Please specify the spine levels and/or other location for the metastatic site(s) if applicable.   |        |        |                 |                |                     |            |  |  |  |  |
|                      | Site 1   | Site 2 | Site 3 | Site 4          | Location       |                     |            |  |  |  |  |
|                      |  |        |        |                 | Adrenal gland  |                     |            |  |  |  |  |
|                      |  |        |        |                 | Bone           |                     |            |  |  |  |  |
|                      |  |        |        |                 | Lung           |                     |            |  |  |  |  |
|                      |  |        |        |                 | Liver          |                     |            |  |  |  |  |
| l E                  |  |        |        |                 | Spine          |                     |            |  |  |  |  |
| Clinica              |  |        |        |                 | Other Non-Bone |                     |            |  |  |  |  |
|                      | Please specify the spine levels, bone location and/or the Other Non-Bone location for the metastatic site(s), if applicable.   |        |        |                 |                |                     |            |  |  |  |  |
|                      |  |        |        |                 |                |                     |            |  |  |  |  |
|                      |  |        |        |                 |                |                     |            |  |  |  |  |
|                      |  |        |        |                 |                |                     |            |  |  |  |  |
|                      | If there are more than 4 metastatic sites, please provide the leastion(s) of the additional metastatic site(s)   |        |        |                 |                |                     |            |  |  |  |  |
|                      | If there are more than 4 metastatic sites, please provide the location(s) of the additional metastatic site(s).  |        |        |                 |                |                     |            |  |  |  |  |
|                      |  |        |        |                 |                |                     |            |  |  |  |  |
|                      |  |        |        |                 |                |                     |            |  |  |  |  |
|                      |  |        |        |                 |                |                     |            |  |  |  |  |

Clinical Information

|  | 1            |              |               | netastatic site(s)?  |  |  |  |  |  |  |
|--|--------------|--------------|---------------|--|--|--|--|--|--|--|
| Site 1   | Site 2       | Site 3       | Site 4        | Treatment Technique  |  |  |  |  |  |  |
|  |              |              |               | Conventional isodose planning, complex                                       |  |  |  |  |  |  |
|  |              |              |               | Electron Beam Therapy  |  |  |  |  |  |  |
|  |              |              |               | 3D conformal   |  |  |  |  |  |  |
|  |              |              |               | Tomotherapy Direct/3D  |  |  |  |  |  |  |
|  |              |              |               | Intensity Modulated Radiation Therapy (IMRT)                                 |  |  |  |  |  |  |
|  |              |              |               | Tomotherapy (IMRT)   |  |  |  |  |  |  |
|  |              |              |               | Rotational Arc Therapy   |  |  |  |  |  |  |
|  |              |              |               | Proton Beam Therapy  |  |  |  |  |  |  |
|  |              |              |               | Stereotactic Body Radiation Therapy (SBRT) (using photons                    |  |  |  |  |  |  |
|  |              |              |               | and 3D planning)   |  |  |  |  |  |  |
|  |              |              |               | Stereotactic Body Radiation Therapy (SBRT) (using photons and IMRT planning) |  |  |  |  |  |  |
|  |              |              |               | Stereotactic Body Radiation Therapy (SBRT) (using protons and                |  |  |  |  |  |  |
|  |              |              |               | 3D planning)   |  |  |  |  |  |  |
|  |              |              |               | Stereotactic Body Radiation Therapy (SBRT) (using protons and                |  |  |  |  |  |  |
|  |              |              |               | IMRT planning)   |  |  |  |  |  |  |
| treated, if  | applicable.  |              |               |  |  |  |  |  |  |  |
| Will image guided radiation therapy (IGRT) be used for the initial phase? ☐ Yes ☐ No ☐   |              |              |               |  |  |  |  |  |  |  |
| Was any  | area being t | treated prev | viously irrac | diated?  |  |  |  |  |  |  |
| If more than one site, will radiation to the metastatic sites be delivered concurrently?   |              |              |               |  |  |  |  |  |  |  |
| If more than one site, will radiation to the metastatic sites be delivered concurrently?  Yes  No  If more than one site, will the same treatment technique be used for all metastatic sites?  Yes  No   |              |              |               |  |  |  |  |  |  |  |
| Please be prepared to submit consult note, results of imaging from the past 60 days and radiation prescription or clinical treatment plan in order to expedite the review process. Failure to provide all relevant information may result in a delay in case processing. |              |              |               |  |  |  |  |  |  |  |
| Additiona  | l Comments   | s/Informatio | n:            | , , ,  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |
|  |              |              |               |  |  |  |  |  |  |  |